The US FDA has given the green light to Biogen (MA, USA) to proceed with the Phase IIIB re-dosing study of aducanumab for patients with Alzheimer’s disease.
Browsing: clinical trial
PTC Therapeutics (NJ, USA) has announced positive topline results from part II of the FIREFISH trial, demonstrating that risdiplam was well tolerated in infants with Type 1 spinal muscular atrophy.
A Phase I clinical trial presents veledimex – a drug-inducible gene therapy approach – as a promising treatment technique for glioblastoma.
Positive results for Emgality® (galcanezumab) have been reported from the CONQUER study in patients who failed previous migraine preventive treatments.
A drug belonging to a new generation of acute migraine headache treatments, termed rimegepant, has been demonstrated to eliminate pain and reduce bothersome symptoms.
A recent clinical trial has demonstrated that the drug, IONIS-HTTRx, is safe for use in people with Huntington’s disease.
Voyager Therapeutics has announced the first patient dosed in RESTORE-1, a Phase II trial of VY-AADC gene therapy for the treatment of Parkinson’s disease.
At ECTRIMS, we had the pleasure of speaking with Marianna Cortese about her research in multiple sclerosis, including her interest in the microbiome.
In a Phase III clinical trial, a novel drug termed GV-971 has shown promise for improving cognition in people with mild-to-moderate Alzheimer’s disease.
The MS-STAT2 trial is underway, with researchers investigating simvastatin as a potential treatment option for individuals with secondary progressive multiple sclerosis.